Company Overview

NeuroOne Medical Technologies Corporation (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. These platform technologies will enable future minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is epilepsy, future potential applications include Parkinson’s disease, Essential tremors, and Dystonia.

Raising the Bar for the Standard of Care

For patients with neurological disorders like epilepsy, non-invasive diagnostics (such as MRIs and EEGs) and treatment using medication are among the first steps taken to diagnose and control symptoms. But for up to 1/3 of epilepsy patients, medication is not enough to control seizure activity or causes unacceptable side effects1.

The next step is surgery, typically a craniotomy, which is highly invasive, requires extended hospitals stays, and carries inherent risk, such as infections. Surgical outcomes rely on the accuracy and specificity of recorded brain activity for surgical resection planning – resect too little and seizures may still be present; resect too much and functional or cognitive abilities may be impaired. With current low-resolution recording technology, many patients who undergo resections still experience seizures. We believe most patients who could benefit from surgical treatment of epilepsy, the perceived risk often outweighs the reward.

NeuroOne believes technology in our pipeline can improve outcomes by:

  • Lowering the risk of infection
  • Reducing inflammation of the brain during recording
  • Increasing accuracy and specificity of recorded brain activity
  • Minimizing invasiveness of the procedure
  • Reducing time-consuming, cumbersome, and costly technical use and management within facilities

By reducing the invasiveness and risk of the procedure while also providing better information for improved surgical planning and outcomes, we believe doctors and patients will choose surgery as a viable option for epilepsy treatment more often, thereby increasing the number of procedures performed in this underpenetrated market.

Recent News and Insights

Management Team

Dave Rosa, President and Chief Executive Officer

Mr. Rosa serves on the board of directors of NeuroOne and is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University, and a BS in Commerce and Engineering from Drexel University.

Mark Christianson, Vice President of Business Development and Marketing

In excess of 15 years of executive sales, sales management, marketing, and project management experience with development stage companies. Prior to NeuroOne, Mr. Christianson held the positions of North American Sales Manager for Cortec Corporation, a manufacturer of specialty chemical products, and Regional Sales Manager for PMT Corporation, a leading manufacturer of products for neurosurgery, orthopedics and plastic surgery. He holds an accounting degree from Augsburg College.

Tom Bachinski, Chief Development Officer

Thirty years of experience in research and development, engineering, and product development of neuro-stimulation devices, sensors and controls in the neurological market. Mr. Bachinski’s experience includes senior level engineering roles at Empi Inc. (acquired by Exos Corporation in 2005), Goodrich Aircraft Sensors Corporation, and other medical device companies. Currently an inventor on 73 patents, he holds a BS in Engineering from the University of Wisconsin, and a Master of Engineering and an MBA from the University of St. Thomas.

Board of Directors

Paul Buckman, Chairman

Mr. Buckman serves as Chairman of the Board of Directors of NeuroOne. He is currently the General Manager of TMVR for LivaNova PLC. Prior to joining LivaNova, Mr. Buckman served as Chief Executive Officer of Conventus Orthopaedics, a Minnesota-based company specializing in peri-articular bone fracture fixation. Prior to LivaNova, Mr. Buckman was Chief Executive Officer of Sentreheart, a medical technology company focused on closure of various anatomic structures. Previously, Mr. Buckman served as Chief Executive Officer and Chairman of Pathway Medical Technologies, a medical device company focused on treatment of peripheral arterial disease. From 2006 to 2008, Mr. Buckman served as Chief Executive Officer of Devax, a developer and manufacturer of drug eluting stents. From 2004 to 2006, Mr. Buckman served as President of the Cardiology Division of St. Jude Medical. From 2001 to 2004, Mr. Buckman was the Chairman of the Board of Directors and Chief Executive Officer of ev3, a Minnesota-based medical device company focused on endovascular therapies that Mr. Buckman founded and developed into an $80 million business. Mr. Buckman has worked in the medical device industry for over 30 years, including ten years at Scimed Life Systems and Boston Scientific Corporation. Mr. Buckman received a Master’s degree in Business Administration and Finance and a B.A. degree in Business Administration from Western Michigan University.

Jeffrey Mathiesen

Mr. Mathiesen serves as a member of the board of directors of NeuroOne. He currently serves as the Chief Financial Officer of Gemphire Therapeutics, a publicly-held clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic disorders, a position he has held since 2015. Prior to joining Gemphire, Mr. Mathiesen served as Chief Financial Officer of Sunshine Heart, a publicly traded medical device company. From 2005 to 2010, Mr. Mathiesen served as Vice President and Chief Financial Officer of Zareba Systems, a manufacturer and marketer of medical products, perimeter fencing and security systems, which was purchased by Woodstream Corporation in 2010. Mr. Mathiesen serves as a director, audit committee chairman and nominating and governance committee member of Sun BioPharma, a publicly traded clinical stage biopharmaceutical company that develops therapies for pancreatic diseases. Mr. Mathiesen received a B.S. in Accounting from the University of South Dakota and is also a Certified Public Accountant.

Suraj Kalia

Mr. Kalia serves as a member of the board of directors of NeuroOne. He currently serves as a Managing Director and Senior Research Analyst at Northland Capital Markets, where he covers the medical technology sector, after rejoining the firm in August 2012. His previous positions include Managing Director and Senior Medical Device Analyst at Rodman & Renshaw Capital Group, Senior Vice President at Madison Williams and Company LLC, Senior Research Analyst at Piper Jaffray Companies, and Project Manager at Entegris as part of the Business Development & Engineering groups. Mr. Kalia has served as a member of the Advisory Board of Levitronix, LLC from 2009 till its acquisition by Thoratec Corp in 2011. He has more than 18 years of experience working in the financial and health care industries. Mr. Kalia has also served as an Adjunct Professor of Finance and taught MBA level courses on Investment Theory and Mergers & Acquisitions at University of St. Thomas. He received a Master’s of Business Administration degree in Finance from the University of St. Thomas in Minneapolis, a Bachelor’s degree in Chemical Engineering from the Indian Institute of Technology in Bombay, India and a Master’s degree in Chemical Engineering from Stevens Institute of Technology in Hoboken, N.J.

Dave Rosa, President and Chief Executive Officer

Mr. Rosa serves on the board of directors of NeuroOne and is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University, and a BS in Commerce and Engineering from Drexel University.

Scientific Advisory Board

Greg Worrell M.D., Ph.D., Chairman

Dr. Worrell is a world-renowned neurologist at Mayo Clinic and has been recognized by the American Epilepsy Society (AES), the American Academy of Neurology (AAN), the American Neurological Association (ANA), and the Citizens United in Research for Epilepsy (CURE) Foundation for his contributions to the field of epilepsy research. Dr. Worrell is a frequent keynote speaker at neurology conferences and has published 90 papers.

Jamie Van Gompel, M.D.

Dr. Van Gompel is a neurosurgeon practicing at Mayo Clinic, specializing in epilepsy surgery utilizing minimally invasive techniques. Dr. Van Gompel has authored or co-authored 87 papers since 2008.

Jorge Gonzalez, M.D., Ph.D.

Dr. Gonzalez is a neurosurgeon practicing at The Cleveland Clinic, specializing in minimally invasive surgical techniques to treat epilepsy. Dr. Gonzalez has authored or contributed to almost 200 publications.

Gregory J. Esper, M.D., M.B.A.

Gregory J. Esper, MD, MBA is Associate Professor and Vice Chair of Clinical Affairs for the Department of Neurology at Emory University School of Medicine. He is also the Director of New Care Models for Emory Healthcare, a role that encompasses Emory’s systemwide approach to clinical effectiveness and innovative care model development, helping Emory to achieve high value care for patients with joy of practice for physicians and other providers. In this role, he is also Emory’s Medical Director for Telemedicine. Dr. Esper is an expert in medical economics and health policy, and currently serves the American Academy of Neurology as Chair of the Health Services Research Subcommittee, and as a member of the Medical Economics and Management committee and the Payment Policy Subcommittee.

Justin Williams, Ph.D.

Dr. Williams is the Department Chair and Vilas Distinguished Achievement Professor at University of Wisconsin. Dr. Williams is credited with multiple publications, patents, and research in the field of thin-film electrodes for neurological recording, ablation, and stimulation.

Joseph Madsen, M.D.

Dr. Madsen is a pediatric neurosurgeon, Director of Epilepsy Surgery at Children’s Hospital in Boston, Massachusetts and Associate Professor of Harvard Medical School. While pursuing his undergraduate degree at the University of Utah, he worked in the lab of Edwin Catmull, the founder of Pixar. That influence led Dr. Madsen to use his own knowledge of software to implement live 3D models for use in neurosurgery. In addition, Dr. Madsen has authored or co-authored over 300 peer-reviewed papers and currently holds nine patents related to improving care in epilepsy and hydrocephalus.

Our Collaborators

Mayo Clinic

NeuroOne entered into a license and development agreement with the Mayo Clinic. NeuroOne licensed worldwide certain know how for the development and commercialization of products, methods and processes related to flexible circuit thin film technology for the recording of tissue and the products developed therefrom.

Wisconsin Alumni Research Foundation

NeuroOne entered into an Exclusive Start-Up Company License Agreement with the Wisconsin Alumni Research Foundation (WARF). WARF granted NeuroOne an exclusive license to make, use and sell, in the U.S. products that employ certain licensed patents for a neural probe array or thin-film micro electrode array and method.